Insmed’s journey to the top

Nearing the end of 3Q25, Insmed is one of the most valuable biotechs in the world and on the precipice of launching what are projected to be multiple billion-dollar blockbuster drugs. But like most biotech stories, it wasn’t a quick journey to the top.

The biotech’s overnight success was 25-plus years in the making, with multiple mergers and different platforms and lead programs along the way. ...